Less than an hour left until STLT steals the show.

 

  

STLT places you within arms reach of tremendous profits.
 

In recent article on NPR.ORG, the former head of the FDA’s orphan drug office went on to say that half of them get through with just one pivotal clinical trial. The article went on to say that it typically requires two or three such trials to approve a mass market drug.

For those approved of orphan drug designation, it could mean big things the company’s stock price.  For example, Dara BioSciences stock soared on orphan drug designation.

Sadly, some companies are manipulating the laws to achieve orphan drug status… even when their drugs are not exactly aimed for patients with rare diseases. For example, AbbVie’s Humira drug…which reached revenue of $7.6 billion in the 3rd quarter of 2016. How can one of their best selling drugs, which treats millions of patients be considered a rare disease?

And how long will they be able to game the system?

Well, last week, President-elect Trump put the pharma industry on notice. In his press conference he boldly said that these companies are getting away with murder.

If he’s serious, there could be a shakeup in the sector. More importantly, the focus could shift towards companies actually looking to make a difference vs. ones that are just trying to game the system.

 

Spotlight Innovation Inc.  (OTCQB:STLT)

 

Spotlight Innovation Inc. (OTCQB: STLT)  is pharmaceutical company that focuses on the development and treatment of rare, emerging, and often-neglected diseases.

They aim to do this through the following strategy:

Acquire intellectual property rights and proprietary medical technologies

Provide development capability and funding in order to fulfill requirements for filing Investigational New Drug (IND) applications

Commercialize technologies thru sale, out-license, and strategic alliance

Generate near-term revenue to support long-term product development programs

 

Not an easy task, however; they’ve got an extremely talented team. Their scientific leadership consists of 3 PhDs and have a scientific board consisting of a PhD from Florida State University and an M.D. from Indiana University. Not to mention, a strong management team and board of directors.

Thus far the company has been working on progress in these areas:

Cancer

Chronic Pain

Zika Virus Infection

Spinal Muscular Atrophy

Refractory Glaucoma

 

It appears that they’re making some strides. For example, they obtained exclusive, worldwide rights to develop and commercialize certain compounds for the treatment of viral infections, including Zika virus infection from Florida State University Research Foundation.

In addition, their investment in Solx, Inc. Now, for those not familiar, SOLX Gold Shunt, is an implantable drainage device which aims at reduce elevated intraocular pressure associated with refractory glaucoma without creating a bleb.

Given these recent developments, you’d think their stock price would be trading at 52-week highs. However, it’s trading at a significant discount when compared to the highs.

Check out the chart on STLT below…

 

 

(Source: TradingView.com)

Technically speaking, on Friday, January 13, 2017 the stock price closed in a “bullish pattern” (according to the Ichimoku Cloud Chart), using 1-hour candlesticks.  If you look at the chart above, you’ll see that it has recently broken above the “cloud.”

Some more stuff traders would be interested include: 60% off it’s 52-week high; according to OTC Markets  around 68k shares trade daily, so it’s thinly traded; market cap of over $13.9m; closed at 65 cents on Friday, January 13, 2017.

Spotlight Innovation Inc.  (OTCQB:STLT)

STLT Spotlight Innovation Inc. identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, STLT leverages their extensive relationships with leading scientists, academic institutions and other sources. STLT provides value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, STLT will endeavor to partner with proven market leaders via sale, out-license or strategic alliance.  

You can read more about STLT and it’s latest news below:

Most Recent Headlines

Spotlight Innovation Appoints John Krohn President and Chief Operating Officer

 

URBANDALE, Iowa, Jan. 10, 2017 /PRNewswire/ — Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company advancing technologies designed to address rare, emerging and neglected diseases, today announced the appointment of Company director John Krohn as President and Chief Operating Officer.

“I am honored and excited to assume these additional leadership roles during this crucial period of the Company’s growth,” said Mr. Krohn. “We are committed to advancing our product development programs, identifying additional opportunities, and creating meaningful value for shareholders.”

Mr. Krohn joined Spotlight Innovation’s Board of Directors in February of 2016. He brings to the Company over three decades of operating and leadership experience across diverse industry sectors. His expertise includes corporate financial management, strategic financial advisory, private and public equity and debt financing, and M&A strategy and execution.

In connection with Mr. Krohn’s appointment, Cristopher Grunewald has stepped down as President and as a director of the Company. Mr. Grunewald will continue to serve as Chief Executive Officer.

“My passion is working with our scientific team to address important unmet medical needs, and this will be the focus of my efforts,” said Mr. Grunewald. “I believe the Company is best served by turning administrative and operational functions over to Mr. Krohn, a consummate professional who is not only qualified to take us to the next level, but who is also a founding and significant equity shareholder.”

Spotlight Innovation Obtains Exclusive, Worldwide Licence From Florida State University Research Foundation to Commercialize Therapeutics for Zika Virus Infection

WEST DES MOINES, Iowa, Dec. 13, 2016 /PRNewswire/ — Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company advancing technologies designed to address rare, emerging and neglected diseases, today announced that the Company has obtained from the Florida State University Research Foundation exclusive, worldwide rights to develop and commercialize certain compounds for the treatment of viral infections, including Zika virus infection. Included among the licensed compounds are those identified in a study1 co-authored by Florida State University Professor Hengli Tang that was published in Nature Medicine in August of this year. Prof. Tang and his research team collaborate with Spotlight Innovation as part of an existing sponsored research agreement (SRA), and he is a member of the Company’s Scientific Advisory Board.

Will Trump Bring Ethics Back To Pharma?  

STLT is a thinly traded stock with a small market cap. Unlike some of the big pharma companies out there, their goal is to help put an end to rare diseases vs. gaming the system to profit more. The stock price is trading at a heavy discount compared to it’s 52-week highs and has some bullishness when evaluating it on an hourly chart.

For your own due diligence, visit here:

http://ir.spotlightinnovation.com/

 

 

 

 

DISCLAIMER

 

 We have been compensated $32.5k  cash via bank wire by a third party,  Sunrise Media, LLC, to conduct investor relations advertising and marketing for STLT. Stellar Media’s business model is to receive financial compensation to promote public companies.  This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only.  We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices.  Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.

 .

 

 

 





1 Comment so far

  1. Acing on January 18th, 2017

    why?